Dornase Alfa Covid-19

Dornase Alfa for Covid-19 Coronavirus

https://en.wikipedia.org/wiki/Dornase_alfa

Covid-19 drug found?

Professor who is working on the treatment against Corona virus, that is to develop drugs. Dr. Ercüment Ovalı announced with the following tweet that he was working on the Covid-19 virus and the drug that was very effective against the virus.

“We were going to announce the name of a drug that we have been working at the lab for 1 month on April 23, but it seems so effective that it can save people’s lives. We did not want to steal from people’s lives. Dornase alpha should be taken to clinical tests in the treatment of alpha patients. Thank you to my heroes. ”

https://rupress.org/jem/article/217/6/e20200652/151683/Targeting-potential-drivers-of-COVID-19-Neutrophil

https://www.pharmac.govt.nz/information-for/covid-19-pharmacs-response/covid-19-medicines-with-amended-access-criteria/covid-19-dornase-alfa/

https://twitter.com/sarahpiercemrs/status/1243480490302156801/photo/1

https://twitter.com/YogenKanthi/status/1240606070881558528

What is Dornase alpha? What does it mean?

It is a human-made version of a protein called DNase in your body and is also known as recombinant human deoxyribonuclease 1 or rhDNase.

It is a highly pure solution of recombinant human deoxyribonuclease I, the enzyme that selectively cleaves DNA.
Dornase alpha hydrolyzes DNA in the sputum / mucus of patients with cystic fibrosis and reduces viscosity in the lungs and provides better clearance of secretions.

Pros of Dornase Alfa

Mucus Clearance: Dornase alfa helps in breaking down the DNA present in the thick mucus, making it easier for individuals with CF to clear the mucus from their airways. This can improve overall lung function and reduce the risk of respiratory infections.

Improved Lung Function: By aiding in mucus clearance, Dornase alfa may contribute to improved lung function in individuals with CF. This can help in reducing symptoms such as shortness of breath and coughing.

Reduced Respiratory Infections: Clearing the thick mucus from the airways may help in reducing the frequency and severity of respiratory infections in individuals with CF. This can be crucial in managing the long-term health of individuals with this condition.

Quality of Life: Improved lung function and reduced respiratory symptoms can contribute to an enhanced quality of life for individuals with CF. They may experience fewer respiratory-related issues, allowing for a more active and normal lifestyle.

Complementary Treatment: Dornase alfa is often used in conjunction with other medications and therapies prescribed for CF, such as bronchodilators, antibiotics, and physical therapy. This multi-pronged approach can help address different aspects of the condition.

Dornase Alpha (DOOR nase AL fa) or Pulmozyme thins the mucus in your lungs. This makes it easier to breathe and helps
prevent lung infections.

Dornase Alfa is a treatment cure or drug against Covid-19 coronavirus?

Cons of Dornase Alfa

Allergic Reactions: Some individuals may experience allergic reactions to Dornase alfa, including difficulty breathing, swelling of the face or throat, and skin rash. It’s crucial to seek medical attention if any signs of an allergic reaction occur.

Respiratory Symptoms: Common side effects of Dornase alfa can include respiratory symptoms such as voice alteration, sore throat, and hoarseness. These symptoms are usually mild, but they can be bothersome for some patients.

Hypersensitivity: Individuals with a history of hypersensitivity to Dornase alfa or any of its components may not be suitable candidates for this medication.

Expense: The cost of Dornase alfa may be a consideration, as it can be an expensive medication. Access and affordability can be significant concerns for some patients.

Limited Efficacy for Some Patients: While Dornase alfa can be effective in improving lung function and reducing respiratory symptoms in many cystic fibrosis patients, it may not work equally well for everyone. Response to the medication can vary among individuals.

Development of Antibodies: In some cases, patients treated with Dornase alfa may develop antibodies against the drug, which can potentially reduce its effectiveness over time.

Interactions with Other Medications: Dornase alfa may interact with other medications, and it is essential to inform healthcare providers about all medications, supplements, or treatments a patient is taking.

What are the possible side effects of dornase alfa (Pulmozyme)?

• an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
• increased difficulty breathing;
• chest pain; or
• fever.

Less serious side effects may be more likely to occur with the use of dornase alfa. Talk to your doctor if you experience any of the following side effects:

• • voice alteration;
  • sore throat;
  • rash;
  • laryngitis;
  • eye redness, irritation, or inflammation; or
  • nasal stuffiness or discharge.

WHO IS Dr. ERCUMENT OVALI?

He was born in Babaeski district of Kırklareli in 1961. He completed his medical education at Hacettepe University Faculty of Medicine, in 19 May University in 1985, and his internal medicine specialization at the same university in 1991, at the Marmara University Faculty of Medicine in 1997.

Ovalı, who started his academic life in 1992 KTU internal diseases, became an Associate Professor in 1994 and a Professor in 1999. While working as a lecturer at the Black Sea Technical University Hematology department, after 1 December 2010, he became the Responsible Manager of Acıbadem Labcell cell laboratory and Kordon blood bank. It has more than 370 publications, 59 of which are articles abroad, and the citation rate of its international publications is 2.5.

He has been working on the development and clinical application of cellular therapy products for the past 18 years. First, he served as the KTÜ Bone Marrow Transplant Center Responsible between 1998-2007. During this period, he served as a member of the Ministry of Health Bone Marrow Transplant Commission and as the chairman of the Cord Blood Banks Coordination Board.

After 2003, he worked as a project coordinator in the establishment of the first GMP laboratory of our country in Trabzon on behalf of KTÜ, and after 2007, he brought 14 different cellular treatment products to our country, mainly Mezenkimal root cells, as the first responsible manager with a production site license under GMP conditions.

Since 1 December 2010, Acıbadem healthcare group hospitals have been the GMP and Cell therapy products consultant, Responsible Manager and Tissue Typing Laboratories, and are working at the Acıbadem Kozyatağı Bone Marrow Transplant Center.

Among his important studies, in addition to TCR alpha beta selection in semi-compatible transplants, he showed that APC depletion caused a 50% reduction in transplantation mortality and complications in a series of 19 diseases.

Another important study in progress is that for the first time in the world, DMD patient showed that allogeneic umbilical cord mesenchymal stem cells and healthy dystrophin gene can be transplanted.

He is married and has 2 children.

Other Post:

Dafalgan Codeine Dosage